BioProtocol unveiled its OpenLabs platform at the DeSci Berlin conference this week, pitching a system that blends artificial intelligence with decentralized funding for scientific research. The platform aims to streamline how projects get off the ground and let the community decide where money goes.
What OpenLabs Brings to the Table
OpenLabs operates as a kind of marketplace for research. It uses AI to help match proposals with potential backers and to manage the administrative side of project development. The decentralized part means funding decisions aren’t made by a single board or foundation. Instead, community governance tools let token holders vote on which studies get support.
The company behind it, BioProtocol, didn’t release technical specifications or a launch date for the full platform. But the demo at DeSci Berlin showed how researchers could submit a proposal, have it scored by an AI model, and then put it to a community vote. The AI is also supposed to track project milestones and flag delays.
Why DeSci Berlin?
DeSci Berlin is a gathering for the “decentralized science” movement — a loose network of projects trying to move research funding away from traditional grant agencies and toward blockchain-based systems. BioProtocol chose the event to introduce OpenLabs to a crowd that’s already skeptical of centralized funding models.
The conference drew about 300 attendees, mostly developers and researchers who work with DAOs and tokenized research grants. BioProtocol’s team spent the day in workshops and one-on-one discussions, showing how OpenLabs might fit into existing DeSci infrastructure.
How It Could Change Research Funding
Today, most research funding goes through government agencies, nonprofits, or corporate R&D budgets. Those systems are slow — a typical grant cycle takes months. OpenLabs promises to cut that to weeks by automating peer review and payment distribution through smart contracts.
Community governance is the other big promise. Instead of a handful of program officers deciding which projects matter, OpenLabs lets anyone holding the platform’s token vote. That could open the door to research that doesn’t fit mainstream priorities — say, niche diseases or unconventional methods.
But there’s a catch. The same community that votes on funding also has to fund the system itself. BioProtocol hasn’t said how it will cover the cost of running the AI models or maintaining the blockchain infrastructure. The platform is still in an early prototype stage.
The Unanswered Question
BioProtocol didn’t announce partners or pilot projects at DeSci Berlin. The company says it’s talking to “several” academic labs and independent researchers, but no names were given. So the real test for OpenLabs will be whether it can attract enough proposals and voters to build a self-sustaining funding loop — or whether it stays a demo.
